Remy
Administrator
Ketotifen is not a well known antihistamine in the US outside of mast cell forums...but it's a great antihistamine because it also works as a mast cell stabilizer. It's available in the US from compounding pharmacies.
And here is 2015 research showing that histamine plays a role in insulin resistance and obesity. These conditions were improved by the addition of 1 mg/day of ketotifen.
Some doctors think ketotifen will also improve leaky gut symptoms if taken 30 minutes before eating.
http://www.collegepharmacy.com/images/download/Woeller_Ketotifen_Protocol.pdf
I am taking ketotifen, though have only been taking 1 mg/day. I'm going to up it to twice a day.
Has anyone else tried ketotifen?
And here is 2015 research showing that histamine plays a role in insulin resistance and obesity. These conditions were improved by the addition of 1 mg/day of ketotifen.
Some doctors think ketotifen will also improve leaky gut symptoms if taken 30 minutes before eating.
http://www.collegepharmacy.com/images/download/Woeller_Ketotifen_Protocol.pdf
I am taking ketotifen, though have only been taking 1 mg/day. I'm going to up it to twice a day.
Has anyone else tried ketotifen?
J Diabetes Complications. 2015 Apr;29(3):427-32. doi: 10.1016/j.jdiacomp.2015.01.013. Epub 2015 Feb 7.
Effect of ketotifen in obese patients with type 2 diabetes mellitus.
El-Haggar SM1, Farrag WF2, Kotkata FA3.
Abstract
AIM:
Mast cells are found to be an important contributor in obesity induced insulin resistance. We evaluate the effect of ketotifen in obese patient with type 2 diabetes (T2DM) treated with glimepiride.
METHOD:
In a randomized controlled study we recruited forty-eight obese patients with T2DM from Internal Medicine Department at Tanta University Hospital, Egypt. They were classified into three groups: group 1, those who received glimepiride (GL) 3mg/d alone; group 2, those who received GL 3mg/d+ketotifen 1mg once daily; and group 3, those who received GL 3mg/d+ketotifen 1mg twice daily. Fasting blood samples were obtained before and 12weeks after treatment for biochemical analysis of glycemic and inflammatory biomarkers. Data were statistically analyzed by paired Student's t-test and one way analysis of variance; p<0.05 was considered statistically significant.
RESULTS:
The obtained data suggested that the addition of ketotifen in twice daily dose has a beneficial effect on all measured parameters except adiponectin. However, glimepiride plus ketotifen once daily only affected the level of inflammatory biomarkers without any significant effect on other parameters.
CONCLUSIONS:
The co-administration of ketotifen twice daily plus glimepiride improves glycemic and inflammatory process in obese patients with T2DM.
Copyright © 2015 Elsevier Inc. All rights reserved.